New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 17, 2014
10:25 EDTSGYP, SGYPSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Synergy Pharmaceuticals' (SGYP) Plecanatide for Irritable Bowel Disease with constipation on an Analyst/Industry conference call to be held on April 17 at 11 am.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 15, 2015
08:21 EDTSGYPSynergy upside largely dependent on buyout, says Citi
Citi doubled its price target for Synergy Pharmaceuticals (SGYP) to $12 from $6 but cautions that upside from current levels is likely dependent on a potential takeout. The firm sees raised expectations into the new the data readout for plecanatide. The drug's effectiveness in chronic idiopathic constipation looks fairly similar to Ironwood's (IRWD) Linzess, Citi tells investors in a research note. It keeps a Buy rating on Synergy.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use